Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
1.
Bone Marrow Transplant ; 52(10): 1406-1415, 2017 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28737775

RESUMO

Fertility preservation is an urgent challenge in the transplant setting. A panel of transplanters and fertility specialists within the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the International BFM Study Group provides specific guidelines. Patients and families should be informed of possible gender- and age-specific cryopreservation strategies that should be tailored according to the underlying disease, clinical condition and previous exposure to chemotherapy. Semen collection should be routinely offered to all postpubertal boys at the diagnosis of any disease requiring therapy that could potentially impair fertility. Testicular tissue collection might be offered to postpubertal boys; nevertheless, its use has been unsuccessful to date. Oocyte collection after hormonal hyperstimulation should be offered to postpubertal girls facing gonadotoxic therapies that could be delayed for the 2 weeks required for the procedure. Ovarian tissue collection could be offered to pre-/post-pubertal girls. Pregnancies have been reported after postpubertal ovarian tissue reimplantation; however, to date, no pregnancy has been reported after the reimplantation of prepubertal ovarian tissue or in vitro maturation of pre-/post-pubertal ovarian tissue. Possible future advances in reproductive medicine could change this scenario. Health authorities should prioritize fertility preservation projects in pediatric transplantation to improve patient care and quality of life.


Assuntos
Antineoplásicos/efeitos adversos , Consenso , Criopreservação/métodos , Preservação da Fertilidade/métodos , Transplante de Células-Tronco Hematopoéticas , Ovário , Testículo , Adolescente , Aloenxertos , Antineoplásicos/uso terapêutico , Criança , Feminino , Humanos , Masculino , Guias de Prática Clínica como Assunto
2.
Bone Marrow Transplant ; 52(7): 1029-1035, 2017 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-28287638

RESUMO

Nowadays, allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a well-established treatment procedure and often the only cure for many patients with malignant and non-malignant diseases. Decrease in short-term complications has substantially contributed to increased survival. Therefore long-term sequelae are reaching the focus of patient care. One of the most important risks of stem cell transplant survivors is infertility. As well as in the field of allo-HSCT also the field of reproductive medicine has achieved substantial advances to offer potential options for fertility preservation in both boys and girls. Access to these procedures as well as their financing differs significantly throughout Europe. As all European children and adolescents should have the same possibility, the Paediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation organised an expert meeting in September 2015. This manuscript describes the recommendations for the diagnosis and pre-emptive procedures that should be offered to all children and adolescents in Europe who have to undergo an allo-HSCT.


Assuntos
Fertilidade , Transplante de Células-Tronco Hematopoéticas , Infertilidade Feminina/prevenção & controle , Infertilidade Masculina/prevenção & controle , Adolescente , Áustria , Criança , Congressos como Assunto , Europa (Continente) , Feminino , Humanos , Masculino , Sociedades Médicas
3.
Bone Marrow Transplant ; 52(2): 201-208, 2017 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-27643863

RESUMO

Therapy for post-transplant relapse of paediatric ALL is limited. Standardised curative approaches are not available. We hereby describe our local procedure in this life-threatening situation. A total of 101 ALL patients received their first allogeneic stem cell transplantation (SCT) in our institution. After relapse, our primary therapeutic goal was to cure the patient with high-dose chemotherapy or specific immunotherapy (HDCHT/SIT) followed by a second SCT from a haploidentical donor (transplant approach). If this was not feasible, low-dose chemotherapy and donor lymphocyte infusions (LDCHT+DLI) were offered (non-transplant approach). A total of 23 patients suffered a post-transplant relapse. Eight patients received HDCHT/SIT, followed by haploidentical SCT in 7/8. Ten received LDCHT+DLI. The eight patients treated with a second transplant and the ten treated with the non-transplant approach had a 4-year overall survival of 56% and 40%, respectively (P=0.232). Prerequisites for successful treatment of post-transplant relapse by either a second transplant or experimental non-transplant approaches are good clinical condition and the capacity to achieve haematological remission by the induction treatment element.


Assuntos
Imunoterapia , Transfusão de Linfócitos , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Transplante de Células-Tronco , Doadores de Tecidos , Adolescente , Aloenxertos , Criança , Pré-Escolar , Feminino , Alemanha , Humanos , Lactente , Masculino , Recidiva , Estudos Retrospectivos
4.
J Cancer Res Clin Oncol ; 141(1): 135-42, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-25081929

RESUMO

PURPOSE: Fertility impairment and recovery after haematopoietic stem cell transplantation (HSCT) have been reported in both sexes, but little is known about how they develop over time. Our aim was to describe the dynamics of fertility impairment and recovery after HSCT. METHODS: We retrieved treatment and fertility data for up to 12 years of 361 paediatric patients with malignant and non-malignant diseases from seven European centres. The patients had been treated with allogeneic HSCT between 2000 and 2005. RESULTS: Development of fertility impairment was observed in males (123/217, 56%) after a median time of 2.6 years (range 0.1-11.4) and in females (82/144, 57%) after 2.3 years (range 0.1-12.0) after HSCT. Different busulfan dosages had only a slight impact on the onset of fertility impairment (busulfan ≥ 16 mg/kg with a median time to fertility impairment of 2.9 vs. 3.9 years after busulfan <14 mg/kg). Recovery from fertility impairment was observed in 17 participants after a median time of 4.1 years (range 1-10.6) in females (10/144, 7%) and 2.0 years (range 1-6.3) in males (7/217, 3 %) after fertility impairment first appeared. CONCLUSIONS: In the light of the dynamics of fertility impairment and recovery in the HSCT patients reviewed, these patients should be counselled comprehensively regarding fertility preservation measures.


Assuntos
Neoplasias Hematológicas/complicações , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Infertilidade/etiologia , Infertilidade/prevenção & controle , Adolescente , Adulto , Criança , Pré-Escolar , Terapia Combinada , Feminino , Seguimentos , Neoplasias Hematológicas/terapia , Humanos , Estudos Longitudinais , Masculino , Estadiamento de Neoplasias , Prognóstico , Estudos Retrospectivos , Transplante Homólogo , Adulto Jovem
6.
Bone Marrow Transplant ; 47(2): 271-6, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21478918

RESUMO

Infertility is a major late effect in patients receiving haematopoietic stem cell transplantation (HSCT). The aim of this study was to determine the proportion of patients having fertility impairment after allogeneic HSCT in childhood/adolescence and to identify the potential risk factors. Treatment and fertility data of paediatric patients with malignant and non-malignant diseases treated with allogeneic HSCT between 2000 and 2005 were collected from seven European centres. Data were obtained for 138 female and 206 male patients after a median follow-up of 6 years (range 3-12). The patients' median age was 13 years (range 4-28) at the time of HSCT and 19 (range 12-35) years at the time of the enquiry. Seven children were born to the overall group, all at term and healthy. Fertility impairment was suspected in 69% males and 83% females. Start of treatment at age 13 years was a risk factor in females (odds ratio (OR) 4.7; 95% confidence interval (CI), 1.5 to 14.9), whereas pre-pubertal therapy was a risk factor in males (OR 0.4; 95% CI, 0.2 to 0.8). The major treatment-related risk factors were BU in females (OR 47.4; 95% CI, 5.4 to 418.1) and TBI in males (OR 7.7; 95% CI, 2.3 to 25.4). In light of the significant proportion of HSCT patients reviewed with impaired fertility, fertility conservation procedures should be considered for all patients undergoing HSCT, particularly those receiving TBI or BU-based preparative regimens.


Assuntos
Fertilidade , Transplante de Células-Tronco Hematopoéticas/métodos , Infertilidade/etiologia , Condicionamento Pré-Transplante/métodos , Adolescente , Adulto , Criança , Pré-Escolar , Feminino , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Humanos , Masculino , Gravidez , Resultado da Gravidez , Estudos Retrospectivos , Fatores de Risco , Taxa de Sobrevida , Condicionamento Pré-Transplante/efeitos adversos , Transplante Homólogo , Adulto Jovem
7.
Klin Padiatr ; 222(6): 399-406, 2010 Nov.
Artigo em Alemão | MEDLINE | ID: mdl-20862634

RESUMO

In Germany and Central Europe, congenital disorders leading to secondary hemochromatosis are rare. The majority of these patients are treated in peripheral medical institutions. As a consequence, the experience of each institution in the treatment of secondary hemochromatosis in patients with congenital anemia is limited. Recent developments concerning new chelating agents, their combination for intensified chelation and new possibilities to diagnose and monitor iron overload have important consequences for the management of patients with secondary hemochromatosis and increase its complexity enormously. Therefore, the development of a guideline for rational and efficient diagnostics and treatment was necessary. The new guideline was developed within a formal consensus process and finally approved by a consensus conference with participants from both the pediatric and adult German hematology societies (GPOH and DGHO). Apart from general information and recommendations, the guideline contains 9 consensus statements on diagnostics (iron status, siderotic complications, chelator side-effects), the start of chelation, indications for intensified chelation, iron elimination in specific disorders, and iron elimination after stem cell transplantation. Here, these consensus statements are presented and discussed in detail. For the complete text of the guideline, please visit the AWMF homepage at http://www.leitlinien.net .


Assuntos
Anemia Aplástica/terapia , Anemia Diseritropoética Congênita/terapia , Quelantes/uso terapêutico , Transfusão de Eritrócitos/efeitos adversos , Hemocromatose/tratamento farmacológico , Hemossiderose/tratamento farmacológico , Anemia Aplástica/sangue , Anemia de Diamond-Blackfan/sangue , Anemia de Diamond-Blackfan/terapia , Anemia Diseritropoética Congênita/sangue , Anemia Falciforme/sangue , Anemia Falciforme/terapia , Quelantes/efeitos adversos , Criança , Desferroxamina/efeitos adversos , Desferroxamina/uso terapêutico , Ferritinas/sangue , Alemanha , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Hemocromatose/sangue , Hemocromatose/diagnóstico , Hemossiderose/sangue , Hemossiderose/diagnóstico , Humanos , Talassemia beta/sangue , Talassemia beta/terapia
8.
Bone Marrow Transplant ; 45(1): 181-9, 2010 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19421174

RESUMO

Enrichment of cell subpopulations is a prerequisite for lineage-specific chimerism analysis (LCA), a frequent approach in follow-up after allo-SCT. An efficient enrichment technique is Magnetic Cell Sorting (MACS) using the AutoMACS separator. However, evaluation of purity, recovery and applicability for PCR-based chimerism analysis of MACS-enriched subpopulations from post-transplant peripheral blood, providing reduced cell numbers and/or unbalanced proportions of subpopulations, is currently unavailable. We performed enrichment of CD3-, CD14-, CD15-, CD19- and CD56-positive subpopulations using 'Whole Blood MicroBeads' and AutoMACS separator in 137 prospectively collected peripheral blood samples from 15 paediatric patients after allo-CD3-/CD19-depleted SCT. Purity was assessed by immune phenotyping. Recovery and applicability for chimerism analysis was evaluated. Excellent purity >90% was achieved in CD14-, CD15-positive cells in 81%, 95% of the isolates and in 86% of CD3 and CD19 isolates, if ACC was >400 cells per mul. Median purity of CD56-positive isolates was 78.9%. Recovery >90% was between 93 (CD56) and 37% (CD15). Conventional and real-time PCR-based chimerism analysis was feasible in virtually all samples. Isolation of cell subpopulations by automated cell enrichment in post-transplant peripheral blood is feasible and fast providing excellent purity and recovery for routine lineage-specific chimerism analysis.


Assuntos
Linhagem da Célula , Separação Celular/métodos , Transplante de Células-Tronco Hematopoéticas/métodos , Subpopulações de Linfócitos/imunologia , Quimeras de Transplante/imunologia , Adolescente , Adulto , Antígenos CD19/imunologia , Complexo CD3/imunologia , Antígeno CD56/imunologia , Criança , Pré-Escolar , Feminino , Citometria de Fluxo/métodos , Humanos , Antígenos CD15/imunologia , Receptores de Lipopolissacarídeos/imunologia , Magnetismo , Masculino , Reação em Cadeia da Polimerase , Polimorfismo Genético , Cuidados Pós-Operatórios , Sequências de Repetição em Tandem
9.
Klin Padiatr ; 219(3): 158-65, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17525910

RESUMO

Since 1962, desferrioxamine (deferoxamine, DFO) has been utilized for the treatment of secondary hemosiderosis. For about 30 years, DFO therapy has been performed as nightly continuous subcutaneous infusion. About 20 years ago, the first oral iron chelator (deferiprone, DFP) was presented. Concerns about potential side effects were responsible for the late acceptance and license of this drug which is limited to the use as second-line therapy for patients with thalassemia major. During recent years, chelation therapy and its evaluation started to progress rapidly. Clinical research and drug development as well as the introduction of new methods for the assessment of iron overload contributed to these advances. By using cardiac T2 (*) MRI it was possible to examine the specific effect of a chelator on myocardial siderosis. Clinical studies using this method indicated superiority of DFP compared to DFO with respect to the treatment of myocardial siderosis. Several retrospective and first prospective clinical trials seem to confirm this observation. In parallel, treatment strategies based on the combination of DFO and DFP have been developed. Using both drugs simultaneously or sequentially, additive and synergistic effects contribute to the fast elimination of iron from different organs at risk for siderotic damage. Deferasirox (DSX) is a recently developed oral chelator which shows good efficacy and tolerability in patients with transfusional hemosiderosis due to various underlying disorders. Long-term studies will define the future importance of DSX for iron chelation treatment. For the first time, there is a choice between three commercially available chelating agents for patients with transfusional iron overload. This will allow a highly effective, individually tailored treatment hopefully leading to a fundamental improvement of patients' life expectancy and quality.


Assuntos
Benzoatos/uso terapêutico , Desferroxamina/uso terapêutico , Hemossiderose/tratamento farmacológico , Quelantes de Ferro/uso terapêutico , Piridonas/uso terapêutico , Triazóis/uso terapêutico , Administração Oral , Benzoatos/efeitos adversos , Benzoatos/farmacocinética , Cardiomiopatias/tratamento farmacológico , Cardiomiopatias/etiologia , Criança , Deferasirox , Deferiprona , Desferroxamina/efeitos adversos , Desferroxamina/farmacocinética , Sinergismo Farmacológico , Quimioterapia Combinada , Meia-Vida , Hemossiderose/sangue , Hemossiderose/etiologia , Humanos , Quelantes de Ferro/efeitos adversos , Imageamento por Ressonância Magnética , Piridonas/efeitos adversos , Piridonas/farmacocinética , Ensaios Clínicos Controlados Aleatórios como Assunto , Reação Transfusional , Triazóis/efeitos adversos , Triazóis/farmacocinética , Talassemia beta/tratamento farmacológico
10.
Curr Med Res Opin ; 22(2): 367-73, 2006 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-16466609

RESUMO

OBJECTIVE: The optimal treatment for early childhood asthma remains controversial. Budesonide (BUD) has shown superiority over placebo in infants, and over disodium cromoglycate (DSCG) in children aged > 2 years. The aim of this double-blind, randomised, parallel-group study was to compare the effectiveness of nebulised BUD and DSCG in asthmatic children aged < 36 months. RESEARCH DESIGN AND METHODS: 82 infants (mean age 18.0 months [range, 11.6-31.2 months]) with suspected asthma (three exacerbations of dyspnoea and wheezing during the past 12 months, with one or more exacerbations in the past 3 months) were treated for 3 months with nebulised BUD (Pulmicort Respules) 0.5 mg/2 mL bid or DSCG 20 mg/2 mL tid. Follow-up was at 6 months. MAIN OUTCOME MEASURES AND RESULTS: Patients treated with BUD had a lower exacerbation rate than DSCG-treated patients after 3 months of treatment (5.4% vs. 31.7%; p = 0.003) and towards the end of follow-up (30% vs. 49%; p = 0.062). During treatment, days without cough were 80% and 65% for BUD and DSCG, respectively (p = 0.014), and nights without cough were 89% and 78%, respectively (p = 0.016). Side-effects were mild and of similar frequency in both groups. CONCLUSIONS: Inhaled nebulised BUD was well tolerated and more effective than nebulised DSCG in reducing the incidence of asthma exacerbations and days with symptoms. These beneficial effects of BUD were maintained throughout the 6-month follow-up.


Assuntos
Antiasmáticos/uso terapêutico , Asma/tratamento farmacológico , Broncodilatadores/uso terapêutico , Budesonida/uso terapêutico , Cromolina Sódica/uso terapêutico , Antiasmáticos/administração & dosagem , Broncodilatadores/administração & dosagem , Budesonida/administração & dosagem , Pré-Escolar , Cromolina Sódica/administração & dosagem , Método Duplo-Cego , Feminino , Alemanha , Humanos , Lactente , Masculino , Nebulizadores e Vaporizadores , Resultado do Tratamento
11.
Arch Dis Child ; 90(12): 1259-63, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16301554

RESUMO

Stem cell transplantation (SCT) is used to cure or greatly ameliorate a wide variety of genetic diseases, ranging from inherent defects of haemopoietic cell production or function to metabolic diseases mostly affecting solid organs. It ranks as one of the most remarkable therapeutic advances of the past 40 years. Despite rapid technological improvements, however, there are still many short term risks and potential long term toxicities. As a consequence, the rapid emergence of alternative therapies (including new drugs, enzyme and gene therapies), necessitate constant re-evaluation of the risk/benefit ratio for each disease and hence the appropriateness of SCT. This review describes the major aspects of the transplant process, indications for transplantation, outcome statistics, and areas where alternative therapies are becoming available.


Assuntos
Doenças Genéticas Inatas/terapia , Doenças Hematológicas/terapia , Transplante de Células-Tronco Hematopoéticas , Doença Enxerto-Hospedeiro/prevenção & controle , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Transplante de Células-Tronco Hematopoéticas/métodos , Transplante de Células-Tronco Hematopoéticas/normas , Humanos , Síndromes de Imunodeficiência/terapia , Erros Inatos do Metabolismo/terapia , Doadores de Tecidos , Condicionamento Pré-Transplante/métodos
12.
J Asthma ; 40(7): 795-802, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-14626336

RESUMO

Bronchial hyperreactivity (BHR) is a key feature of asthma, but measurement can usually not be achieved in infants with standard lung function tests. We investigated the safety and tolerability of methacholine challenge in infants with recurrent wheezing episodes. 78 methacholine challenges in 51 sedated infants aged 12-36 months with recurrent wheezing episodes were performed. Methacholine challenge was stopped when clinical signs (coughing, wheezing, or cyanosis) or a drop of oxygen saturation (SPO2) of at least 5% or a drop of transcutaneous oxygen tension (PtcO2) of at least 0.8 kPa or an increase of resistance (RrsSO), of 50% by single occlusion technique were observed. Prior to methacholine challenge, all children were symptom-free with a mean SPO2 of 97.4% (SD 1.80%). In 48 cases (61.5%), no clinical sign was observed, 17 (21.8%) coughed, and 13 (16.7%) wheezed. A mean reduction of SPO2 of 5.0% (SD 3.89%) for the entire population was observed. In 15 of 78 cases, a decrease of SPO2 <90% occurred. This SPO2 drop was short-lasting and resolved spontaneously or after bronchodilator inhalation. Infants whose SPO2 dropped <90% showed a greater increase of RrsSO compared to infants who did not drop <90% (133% vs. 65% RrsSO increase, p<0.001). Methacholine challenge, using a combination of clinical observation, monitoring of SPO2 and PtcO2, and airway resistance using the single-occlusion technique, is a safe and tolerable tool to measure the BHR in infants with recurrent wheezing episodes.


Assuntos
Hiper-Reatividade Brônquica/diagnóstico , Testes de Provocação Brônquica , Broncoconstritores , Cloreto de Metacolina , Sons Respiratórios , Resistência das Vias Respiratórias , Monitorização Transcutânea dos Gases Sanguíneos , Testes de Provocação Brônquica/efeitos adversos , Broncoconstritores/efeitos adversos , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Cloreto de Metacolina/efeitos adversos , Oxigênio/sangue
13.
Klin Padiatr ; 214(6): 327-31, 2002.
Artigo em Alemão | MEDLINE | ID: mdl-12424679

RESUMO

BACKGROUND: Enterovirus infections are among the most common causes of aseptic meningitis. Worldwide there are reports about recurring outbreaks, especially during the summer. They are favoured by conditions of bad hygiene and contaminated water, transmission is predominantly through the faeco-oral route or by droplet infection. The most common species are Coxsackie B and ECHO (Enteric Cytopathogenic Human Orphan) virus. ECHO viruses have a worldwide distribution and usually occur as "summer flu" or aseptic meningitis and meningoencephalitis in toddlers and infants. Type 30 caused an outbreak of aseptic meningitis in the Rhein-Main region in summer 1997. During five months 63 children younger than 16 years were reported. PATIENTS AND METHODS: During this outbreak 18 children with prooved enterovirus infections were treated at the Frankfurt/Main University Children's Hospital. Standardized infectiological diagnostic procedures were performed and risc factors, clinical symptoms, inflammatory marker, neurophysiological findings (electroencephalography, evoked potentials) and outcome were assessed. RESULTS: The affected children were between 3 and 11 years old. Clinical symptoms were cephalgia, nausea, vomiting, meningism and seizures with fever. Virus isolation from faecal and cerebrospinal fluid (CSF) samples and the use of polymerase chain reaction (PCR) was superior to serological methods. Erythrocyte sedimentation rates showed more significant increase than C-reactive protein (CRP) and blood leukocytes. CSF pleocytosis showed high variation. Clinical course as well as prognosis and outcome were favourable. CONCLUSION: Virusisolation in stool and CSF is most promising in the diagnostic of cerebral enterovirus infections. Usually the outcome is favourable, encephalitis can occur as serious complication.


Assuntos
Enterovirus Humano B , Infecções por Enterovirus , Meningite Viral , Adolescente , Líquido Cefalorraquidiano/virologia , Criança , Pré-Escolar , Eletroencefalografia , Enterovirus Humano B/isolamento & purificação , Infecções por Enterovirus/diagnóstico , Infecções por Enterovirus/virologia , Fezes/virologia , Seguimentos , Hospitalização , Humanos , Meningite Viral/diagnóstico , Meningite Viral/virologia , Inquéritos e Questionários , Fatores de Tempo
15.
Am J Med Genet ; 78(5): 455-60, 1998 Aug 06.
Artigo em Inglês | MEDLINE | ID: mdl-9714013

RESUMO

We report on the unprecedented combination of two recessively inherited disorders, the kyphoscoliosis type of Ehlers-Danlos syndrome (EDS type VI) and cystic fibrosis (CF), in two sibs born to consanguineous Turkish parents. Because of failure to thrive and bronchitis CF was diagnosed in the index patient early whereas EDS VI was recognized only very late. Both patients had marked muscular hypotonia at birth, delayed gross motor development, progressive kyphoscoliosis, joint dislocations, Marfanoid habitus, hypertrophic and atrophic scars, and osteopenia. EDS VI was proven by collagen studies and the pathognomonic pattern of urinary pyridinolines. Because the genes coding for the two disorders are located on different chromosomes and a chromosomal rearrangement was excluded, we conclude that their combination is a chance association. The cardiopulmonary impairment common to both diseases makes the prognosis dismal.


Assuntos
Fibrose Cística/complicações , Síndrome de Ehlers-Danlos/complicações , Aminoácidos/urina , Colágeno/análise , Consanguinidade , Fibrose Cística/diagnóstico , Fibrose Cística/genética , Síndrome de Ehlers-Danlos/diagnóstico , Feminino , Genes Recessivos , Deformidades Congênitas da Mão/diagnóstico por imagem , Humanos , Hidroxilisina/metabolismo , Recém-Nascido , Núcleo Familiar , Linhagem , Pró-Colágeno-Lisina 2-Oxoglutarato 5-Dioxigenase/deficiência , Prognóstico , Radiografia , Escoliose/diagnóstico por imagem , Turquia
16.
Acta Derm Venereol ; 76(4): 287-90, 1996 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-8869686

RESUMO

Cultured skin fibroblasts derived from old (> 60 years) donors differ in various morphological and functional aspects from cells obtained from young (< 20 years) donors. We were interested in whether fibroblasts obtained from old and young donors differ in their cellular response to interleukin-1 beta, a cytokine which has been shown to affect the synthesis of extracellular matrix proteins in human dermal fibroblasts. Therefore the expression of interstitial collagen (type I), minor collagen (type VI) and interstitial collagenase genes was investigated, using fibroblasts derived from either old or young donors. Fibroblasts were incubated in the absence or presence of interleukin-1 beta (5 units/ml, 50 units/ml, 500 units/ml) for 48 h. Total RNA was isolated and mRNA levels were determined by Northern and dot blot analysis. Comparing the synthetic response of fibroblasts obtained from young and old donors, we observed a marked increase of the inhibition of type I and type VI collagen expression and the stimulation of interstitial collagenase in the aged fibroblasts. These results suggest that physiological ageing in human fibroblasts is associated with an altered responsiveness to interleukin-1 beta.


Assuntos
Envelhecimento/metabolismo , Colágeno/genética , Regulação da Expressão Gênica , Interleucina-1/farmacologia , Pele/metabolismo , Adolescente , Adulto , Envelhecimento/genética , Northern Blotting , Células Cultivadas , Colágeno/análise , Colágeno/antagonistas & inibidores , Colagenases/análise , Colagenases/genética , Proteínas da Matriz Extracelular/análise , Proteínas da Matriz Extracelular/genética , Fibroblastos/citologia , Fibroblastos/metabolismo , Gliceraldeído-3-Fosfato Desidrogenases , Humanos , Immunoblotting , Pessoa de Meia-Idade , Hibridização de Ácido Nucleico , RNA/análise , RNA/genética , RNA Mensageiro/análise , RNA Mensageiro/genética , Pele/citologia
17.
Wein; Holder; 1900. 1055 p. ilus, ^e25cm.(Specielle Pathologie und Therapie, 24).
Monografia em Alemão | LILACS-Express | Sec. Est. Saúde SP, SESSP-ILSLACERVO, Sec. Est. Saúde SP | ID: biblio-1230989
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA